This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tognon, C. Articles by Sorensen, P. H. B. Search for Related Content PubMed PubMed Citation Articles by Tognon, C. Articles by Sorensen, P. H. B.

The Chimeric Protein Tyrosine Kinase ETV6-NTRK3 Requires both Ras-Erk1/2 and PI3-Kinase-Akt Signaling for Fibroblast Transformation¹

Departments of Pathology and Pediatrics, BC Research Institute for Children’s and Women’s Health, Vancouver, British Columbia, V6H 3V4 [C. T., M. G., E. K., K. M., P. H. B. S.], and Department of Medical Genetics, Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, British Columbia, V5Z 4E6 [R. K.], Canada

There is increasing interest in the potential role of the NTRK family of neurotrophin receptors in human neoplasia. These receptor protein tyrosine kinases (PTKs) are well-known mediators of neuronal cell survival and differentiation, but altered NTRK signaling has also been implicated in mesenchymal, hematopoietic, and epithelial malignancies. We recently identified a novel gene fusion involving one of the neurotrophin receptor genes, NTRK3, in the pediatric solid tumor, congenital fibrosarcoma. In these tumors (and subsequently demonstrated in several other human malignancies), a t(12;15)(p13;q25) rearrangement fuses the 3' portion of the ETV6 gene with exons encoding the PTK domain of NTRK3. The resulting ETV6-NTRK3 fusion protein functions as a chimeric PTK with potent transforming activity. However, previous studies failed to detect interactions between ETV6-NTRK3 and molecules known to link wild-type NTRK3 to its two major effector pathways, namely the Ras-Raf1-Mek1-Erk1/2 mitogenic pathway or the phosphatidylinositol 3'-kinase pathway leading to activation of the AKT survival factor. Therefore, it remains unknown whether ETV6-NTRK3 transformation involves altered NTRK3 signaling. We now report that ETV6-NTRK3 expression in NIH3T3 cells leads to constitutive activation of Mek1 and Akt, as well as to constitutively high expression of cyclin D1. ETV6-NTRK3-induced soft agar colony formation was almost completely abolished by inhibition of either the Ras-Raf1-Mek1-Erk1/2 or the phosphatidylinositol 3'-kinase-Akt pathway. Moreover, this inhibition dramatically reduced expression of cyclin D1. Our results indicate that ETV6-NTRK3 transformation involves a link between known NTRK3 signaling pathways and aberrant cell cycle progression and that Mek1 and Akt activation act synergistically to mediate these effects.

This article has been cited by other articles:

				R. Karni, Y. Hippo, S. W. Lowe, and A. R. Krainer The splicing-factor oncoprotein SF2/ASF activates mTORC1 PNAS, October 7, 2008; 105(40): 15323 - 15327. [Abstract] [Full Text] [PDF]

				W. Jin, C. Yun, J. Jeong, Y. Park, H.-D. Lee, and S.-J. Kim c-Src Is Required for Tropomyosin Receptor Kinase C (TrkC)-induced Activation of the Phosphatidylinositol 3-Kinase (PI3K)-AKT Pathway J. Biol. Chem., January 18, 2008; 283(3): 1391 - 1400. [Abstract] [Full Text] [PDF]

				H.-G. Kang, J. M. Jenabi, J. Zhang, N. Keshelava, H. Shimada, W. A. May, T. Ng, C. P. Reynolds, T. J. Triche, and P. H.B. Sorensen E-Cadherin Cell-Cell Adhesion in Ewing Tumor Cells Mediates Suppression of Anoikis through Activation of the ErbB4 Tyrosine Kinase Cancer Res., April 1, 2007; 67(7): 3094 - 3105. [Abstract] [Full Text] [PDF]

				W. Jin, C. Yun, A. Hobbie, M. J. Martin, P. H.B. Sorensen, and S.-J. Kim Cellular Transformation and Activation of the Phosphoinositide-3-Kinase-Akt Cascade by the ETV6-NTRK3 Chimeric Tyrosine Kinase Requires c-Src Cancer Res., April 1, 2007; 67(7): 3192 - 3200. [Abstract] [Full Text] [PDF]

				M. J. Martin, N. Melnyk, M. Pollard, M. Bowden, H. Leong, T. J. Podor, M. Gleave, and P. H. B. Sorensen The Insulin-Like Growth Factor I Receptor Is Required for Akt Activation and Suppression of Anoikis in Cells Transformed by the ETV6-NTRK3 Chimeric Tyrosine Kinase. Mol. Cell. Biol., March 1, 2006; 26(5): 1754 - 1769. [Abstract] [Full Text] [PDF]

				W. Jin, B.-C. Kim, C. Tognon, H.-J. Lee, S. Patel, C. L. Lannon, J. M. Maris, T. J. Triche, P. H. B. Sorensen, and S.-J. Kim The ETV6-NTRK3 chimeric tyrosine kinase suppresses TGF-{beta} signaling by inactivating the TGF-{beta} type II receptor PNAS, November 8, 2005; 102(45): 16239 - 16244. [Abstract] [Full Text] [PDF]

				C. E. Tognon, C. D. Mackereth, A. M. Somasiri, L. P. McIntosh, and P. H. B. Sorensen Mutations in the SAM Domain of the ETV6-NTRK3 Chimeric Tyrosine Kinase Block Polymerization and Transformation Activity Mol. Cell. Biol., June 1, 2004; 24(11): 4636 - 4650. [Abstract] [Full Text] [PDF]

				C. L. Lannon, M. J. Martin, C. E. Tognon, W. Jin, S.-J. Kim, and P. H. B. Sorensen A Highly Conserved NTRK3 C-terminal Sequence in the ETV6-NTRK3 Oncoprotein Binds the Phosphotyrosine Binding Domain of Insulin Receptor Substrate-1: AN ESSENTIAL INTERACTION FOR TRANSFORMATION J. Biol. Chem., February 20, 2004; 279(8): 6225 - 6234. [Abstract] [Full Text] [PDF]